Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Philip T, Leese"'
Autor:
Stuart Oliver, David Millson, Paul D. Martin, Philip T. Leese, Michael Gillen, Dominic Surry, Clive Brealey, David Lau, David J. Sweeny
Publikováno v:
Clinical Pharmacology in Drug Development. 5:170-179
Fostamatinib is a prodrug that undergoes gastrointestinal tract dephosphorylation to form the active metabolite, R406. Here we report its cytochrome P450-inducing potential. In vitro, R406 3 and 10 μM induced CYP2C8 to levels representing 53% and 75
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::351e92f4de8689a4ec9b21b7dd42b8ef
https://doi.org/10.1002/cpdd.243
https://doi.org/10.1002/cpdd.243
Publikováno v:
Clinical Pharmacology in Drug Development
Cachexia occurs in up to 80% of patients with advanced cancer and is characterized by involuntary weight loss, frequently accompanied by anorexia and altered metabolism.1–5 It is associated with poorer survival, a decline in physical functioning an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::681a68c127be598169dd9c6cbd8ffd6e
http://europepmc.org/articles/PMC4657463
http://europepmc.org/articles/PMC4657463
Autor:
Enriqueta Felip, Yuichiro Ohe, Pasi A. Jänne, Mireille Cantarini, Malcolm R Ranson, Kathryn H. Brown, Sang-We Kim, Paul A. Dickinson, Karthick Vishwanathan, David Planchard, Dong Wan Kim, Philip T. Leese
Publikováno v:
Cancer chemotherapy and pharmacology. 77(4)
Osimertinib (AZD9291) 80 mg once daily is approved by the US FDA for the treatment of patients with metastatic EGFR T790M-positive NSCLC whose disease has previously progressed on EGFR-TKI therapy. Osimertinib PK was evaluated to define the dose and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37b7419acd1e975d47216ee2f417b55b
https://pubmed.ncbi.nlm.nih.gov/26902828
https://pubmed.ncbi.nlm.nih.gov/26902828
Autor:
Jill Chappell, Celedon Gonzales, Larry Ereshefsky, Lu Zhang, Philip T Leese, David Hoelscher, Malcolm I. Mitchell, J. T. Callaghan, Mark Leibowitz, M. Derby
Publikováno v:
Journal of Cardiovascular Pharmacology. 49:384-393
The effects of supratherapeutic dosages of duloxetine, a serotonin and norepinephrine reuptake inhibitor, on blood pressure and pulse rate were assessed in a multicenter, double-blind, randomized, placebo-controlled, crossover study in 117 healthy wo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed4d5797b8d5a84bb5283b50c492b204
https://doi.org/10.1097/fjc.0b013e31804d1cce
https://doi.org/10.1097/fjc.0b013e31804d1cce
Autor:
Philip T Leese, Mary Pat Knadler, Jennie Lin Francis, David Hoelscher, Lu Zhang, J. T. Callaghan, Larry Ereshefsky, David S. Small, Durisala Desaiah, Celedon Gonzales, Jill Chappell, M. Derby, Mark Leibowitz
Publikováno v:
Journal of Cardiovascular Pharmacology. 49:146-153
The electrophysiological effects of duloxetine at supratherapeutic exposures were evaluated to ensure compliance with regulatory criteria and to assess the QT prolongation potential.Electrocardiograms were collected in a multicenter, double-blind, ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33e8266cf35a63eff0bc8cfa87bbcff5
https://doi.org/10.1097/fjc.0b013e318030aff7
https://doi.org/10.1097/fjc.0b013e318030aff7
Autor:
Fred L. Johnson, Philip T. Leese, D.J. Kellerman, Anthony W. Fox, Todd A. Durham, Christopher S. Crean, Ramesh Krishnamoorthy, José L. Boyer
Publikováno v:
Platelets. 18:346-356
P2Y(12) receptors participate in ADP-induced activation and aggregation of human platelets. INS50589, a selective P2Y(12) receptor antagonist, is being developed for use where controlled, reversible modulation of the platelet hemostatic function is n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::182d65b330b8bde780d7efb869d7d28b
https://doi.org/10.1080/09537100701268741
https://doi.org/10.1080/09537100701268741
Publikováno v:
Journal of Clinical Pharmacology. 43:504-513
The effects of the new cyclooxygenase (COX)-2 selective inhibitor, valdecoxib (40 mg bid; n = 17), on platelet function were evaluated, along with ibuprofen (800 mg tid; n = 15) and placebo (n = 15), in healthy elderly subjects (65-85 years) in this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::082f3b5f6637fd4edfb7714b96b5cb5e
https://doi.org/10.1177/0091270003043005005
https://doi.org/10.1177/0091270003043005005
Publikováno v:
The American Journal of Emergency Medicine. 20:275-281
The platelet effects of a supratherapeutic dose of the new cyclooxygenase (COX)-2 specific inhibitor, valdecoxib (40 mg twice a day), naproxen 500 mg twice a day, diclofenac 75 mg twice a day, and placebo were compared in 62 healthy adult subjects in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb7a2320e982341493e4345433f15d22
https://doi.org/10.1053/ajem.2002.32635
https://doi.org/10.1053/ajem.2002.32635
Autor:
Todd Leathers, Jeffrey S. Barrett, James W. Hainer, Michael J. Fossler, Donna S. Cox, Christopher A. Assaid, Philip T. Leese
Publikováno v:
Thrombosis and Haemostasis. 87:817-823
SummaryThis pharmacodynamic study examined weight-based dosing of the low molecular weight heparin (LMWH), tinzaparin, in heavyweight/obese subjects. Single doses (175 and 75 IU/kg) were administered subcutaneously (SC) to 37 healthy heavy-weight sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::121318d43ca47e9c7f7dc69d63de5673
https://doi.org/10.1055/s-0037-1613090
https://doi.org/10.1055/s-0037-1613090
Autor:
Philip T. Leese, Eleanor Lisbon, Paul D. Martin, Susanne Johansson, Stuart Oliver, David Mathews, Jessica Read, Yan Li, M. Steinberg
Publikováno v:
Clinical pharmacokinetics. 53(9)
Vandetanib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and rearranged during transfection (RET) signalling, indicated for the treatment of medullary thyroid cancer. We inves
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f3dd03fa3b439118f4794dbf20c823c
https://pubmed.ncbi.nlm.nih.gov/25117183
https://pubmed.ncbi.nlm.nih.gov/25117183